Compare NetEase Inc (NTES) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Sanofi SA — how do they compare? NetEase Inc trades at $124.42 (market cap $82.75B), while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| NTES | SNY | |
|---|---|---|
Market Cap | $82.75B | $104.30B |
Sector | Media | Health |
52-Week High | $159.34 | $52.34 |
52-Week Low | $109.26 | $41.33 |
Enterprise Value | $59.05B | $124.19B |
Dividend Yield | 2.36% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $124.26, down 6.86% over 24 hours, with a P/E of 16.31 and P/S of 4.86. Recent earnings show a beat in Q1 2026 but misses in prior quarters. The company maintains strong profitability with a net income margin of 29.84% and ROE of 22.12%. Technical indicators signal a bullish trend, supported by positive analyst sentiment with 82% buy ratings.
The outlook for NTES is positive due to robust fundamentals and international expansion potential. Risks include earnings volatility and competitive pressures in the gaming sector. Upside is supported by a $0.72 dividend and strong cash flow generation, though investors should monitor quarterly performance against expectations.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
